NY-SECURITYSCORECARD
18.1.2023 08:01:36 CET | Business Wire | Press release
SecurityScorecard, the global leader in cybersecurity ratings, today announced the results of its new report, Addressing the Trust Deficit In Critical Infrastructure, which revealed 48% of critical manufacturing organizations ranked “C,” “D,” or “F” on SecurityScorecard’s security ratings platform. Published during the World Economic Forum (WEF) Annual Meeting, the report analyzed the current state of cyber resilience in the critical infrastructure sectors such as Energy, Chemical, Healthcare, and others, as designated by the Cybersecurity and Infrastructure Security Agency (CISA). Organizations with an “A” security rating are 7.7 times less likely to sustain a breach than those with an “F” rating.
“Security ratings are a trusted barometer of cyber resilience and the time is now for policymakers and organizations to make cyber risk measurement mandatory,” said Aleksandr Yampolskiy, co-founder and CEO of SecurityScorecard. “Cyberattacks in the last 10 years have gotten much worse, more complex, and increasingly have targeted critical infrastructure, thereby undermining the public’s trust in the cyber resilience of our global economy.”
SecurityScorecard provides comprehensive security ratings, automated assessments, and guidance from industry experts, providing a patented and easy-to-understand A-F graded scorecards for improved communication, effective compliance reporting, and more informed decision-making.
According to the World Economic Forum, only 19% of cyber leaders feel confident that their organizations are cyber resilient. SecurityScorecard recently joined the World Economic Forum Global Innovators Community, contributing to WEF’s Centre for Cybersecurity’s initiative to address systemic challenges, improve trust, and build cyber resilience. Yampolskiy is attending the WEF Annual Meeting in Davos to engage with the world’s foremost public- and private-sector leaders on mitigating global cyber risk, including within critical infrastructure.
Critical Manufacturing Patching Cadence Falls Amid Escalating Attack Cadence
Cyber incidents affecting critical infrastructure, once comparatively rare, have become far more frequent in recent years as nation-states and their proxies escalate their pursuit of geopolitical objectives. Data from the Federal Bureau of Investigation showed that 14 of the 16 sectors considered critical infrastructure by the U.S. government experienced at least one ransomware attack in 2021.
SecurityScorecard assessed these industries to measure their current state of cyber resilience. It found that critical manufacturing is highly vulnerable based on analysis of all organizations under that category in The Forbes Global 2000 list. SecurityScorecard considers 10 factors when developing an organization’s security rating. Of those 10, the patching cadence ‘factor’ for critical manufacturing experienced a significant drop from 2021 to 2022, moving from 88 (B) to 76 (C).
High and Medium-Severity CVEs Strain Resources
The decline in patching is likely due to an increased volume of vulnerabilities. Critical manufacturing experienced a 38% year-over-year increase in high severity vulnerabilities. In 2022 alone, 76% of critical manufacturing organizations have high and medium-severity CVEs.
These CVEs may, in some cases, facilitate ransomware groups’ targeting of organizations in the sector. Manufacturers experienced an increase in malware infections from 2021 to 2022. In 2022, 37% of critical manufacturing organizations had malware infections.
“While investing in more technology might seem burdensome to resource-constrained critical infrastructure operators, the reality is that cybersecurity ratings technology is extremely cost-effective, especially when you consider the catastrophic cost of a breach is $9.44 million on average for U.S. organizations,” continued Yampolskiy. “By leveraging security ratings, these organizations have a simple way to build resilience and make more informed decisions to strengthen their cyber defenses by confidently measuring risk and quantifying the trustworthiness of their partners, contractors, third-and fourth-party vendors, and supply chains.”
To view the full research paper, please visit: https://resources.securityscorecard.com/davos-2023/addressing-the-trust-deficit
About SecurityScorecard
Funded by world-class investors including Evolution Equity Partners, Silver Lake Waterman, Sequoia Capital, GV, Riverwood Capital, and others, SecurityScorecard is the global leader in cybersecurity ratings with more than 12 million companies continuously rated. Founded in 2013 by security and risk experts Dr. Aleksandr Yampolskiy and Sam Kassoumeh, SecurityScorecard's patented rating technology is used by over 30,000 organizations for enterprise risk management, third-party risk management, board reporting, due diligence, cyber insurance underwriting, and regulatory oversight. SecurityScorecard is the first cybersecurity ratings company to offer digital forensics and incident response services, providing a 360-degree approach to security prevention and response for its worldwide customer and partner base. SecurityScorecard continues to make the world a safer place by transforming the way companies understand, improve and communicate cybersecurity risk to their boards, employees and vendors. Every organization has the universal right to their trusted and transparent Instant SecurityScorecard rating. For more information, visit securityscorecard.com or connect with us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005416/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
